Application of berberine on treating type 2 diabetes mellitus
The consensus emerging from these programs is that timing of intervention may matter more than which specific GLP-1 is used
No human clinical trial has validated a dosing range for IGF-1 LR3
Melanocortin receptor agonists and signalling mechanisms
Thomas DA, Cortes J, Giles F, OBrien S, Faderl S, Garcia-Manero G, Beran M, Koller C, Andreeff M , Kornblau S, Keating M, Kantarjian H
What patients do report, usually transiently, includes a brief injection-site reaction, mild flushing across the face or chest for a few minutes after injection, and occasional tingling in the hands or feet that can signal the dose needs adjusting